These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31940699)

  • 1. JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency.
    Alsohime F; Martin-Fernandez M; Temsah MH; Alabdulhafid M; Le Voyer T; Alghamdi M; Qiu X; Alotaibi N; Alkahtani A; Buta S; Jouanguy E; Al-Eyadhy A; Gruber C; Hasan GM; Bashiri FA; Halwani R; Hassan HH; Al-Muhsen S; Alkhamis N; Alsum Z; Casanova JL; Bustamante J; Bogunovic D; Alangari AA
    N Engl J Med; 2020 Jan; 382(3):256-265. PubMed ID: 31940699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy.
    Gruber C; Martin-Fernandez M; Ailal F; Qiu X; Taft J; Altman J; Rosain J; Buta S; Bousfiha A; Casanova JL; Bustamante J; Bogunovic D
    J Exp Med; 2020 May; 217(5):. PubMed ID: 32092142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
    Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
    J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
    Fetter T; Rios GC; Niebel D; Bieber T; Wenzel J
    Acta Derm Venereol; 2020 May; 100(10):adv00144. PubMed ID: 32285135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
    Goker Bagca B; Biray Avci C
    Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.
    Lobo PB; Guisado-Hernández P; Villaoslada I; de Felipe B; Carreras C; Rodriguez H; Carazo-Gallego B; Méndez-Echevarria A; Lucena JM; Aljaro PO; Castro MJ; Noguera-Uclés JF; Milner JD; McCann K; Zimmerman O; Freeman AF; Lionakis MS; Holland SM; Neth O; Olbrich P
    J Clin Immunol; 2022 Aug; 42(6):1193-1204. PubMed ID: 35507130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
    Vannucchi AM; Sordi B; Morettini A; Nozzoli C; Poggesi L; Pieralli F; Bartoloni A; Atanasio A; Miselli F; Paoli C; Loscocco GG; Fanelli A; Para O; Berni A; Tassinari I; Zammarchi L; Maggi L; Mazzoni A; Scotti V; Falchetti G; Malandrino D; Luise F; Millotti G; Bencini S; Capone M; Piccinni MP; Annunziato F; Guglielmelli P;
    Leukemia; 2021 Apr; 35(4):1121-1133. PubMed ID: 32814839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mosaic IL6ST variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy.
    Materna-Kiryluk A; Pollak A; Gawalski K; Szczawinska-Poplonyk A; Rydzynska Z; Sosnowska A; Cukrowska B; Gasperowicz P; Konopka E; Pietrucha B; Grzywa TM; Banaszak-Ziemska M; Niedziela M; Skalska-Sadowska J; Stawiński P; Śladowski D; Nowis D; Ploski R
    Hum Mol Genet; 2021 Apr; 30(3-4):226-233. PubMed ID: 33517393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
    Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
    Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Roles of USP18: From Biology to Pathophysiology.
    Kang JA; Jeon YJ
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Biallelic
    Alghamdi MA; Mulla J; Saheb Sharif-Askari N; Guzmán-Vega FJ; Arold ST; Abd-Alwahed M; Alharbi N; Kashour T; Halwani R
    Front Immunol; 2020; 11():599564. PubMed ID: 33488593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK inhibition in the type I interferonopathies.
    Crow YJ; Neven B; Frémond ML
    J Allergy Clin Immunol; 2021 Oct; 148(4):991-993. PubMed ID: 34375617
    [No Abstract]   [Full Text] [Related]  

  • 14. Complex Autoinflammatory Syndrome Unveils Fundamental Principles of JAK1 Kinase Transcriptional and Biochemical Function.
    Gruber CN; Calis JJA; Buta S; Evrony G; Martin JC; Uhl SA; Caron R; Jarchin L; Dunkin D; Phelps R; Webb BD; Saland JM; Merad M; Orange JS; Mace EM; Rosenberg BR; Gelb BD; Bogunovic D
    Immunity; 2020 Sep; 53(3):672-684.e11. PubMed ID: 32750333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-λ4 desensitizes the response to IFN-α treatment in chronic hepatitis C through long-term induction of USP18.
    Fan W; Xie S; Zhao X; Li N; Chang C; Li L; Yu G; Chi X; Pan Y; Niu J; Zhong J; Sun B
    J Gen Virol; 2016 Sep; 97(9):2210-2220. PubMed ID: 27302182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
    Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
    Front Immunol; 2020; 11():620098. PubMed ID: 33658996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.
    Febvre-James M; Lecureur V; Augagneur Y; Mayati A; Fardel O
    Int Immunopharmacol; 2018 Jan; 54():354-365. PubMed ID: 29202299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.
    Mortara A; Mazzetti S; Margonato D; Delfino P; Bersano C; Catagnano F; Lauriola M; Grosso P; Perseghin G; Ippoliti G
    Clin Transl Sci; 2021 May; 14(3):1062-1068. PubMed ID: 33403775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome.
    Meuwissen ME; Schot R; Buta S; Oudesluijs G; Tinschert S; Speer SD; Li Z; van Unen L; Heijsman D; Goldmann T; Lequin MH; Kros JM; Stam W; Hermann M; Willemsen R; Brouwer RW; Van IJcken WF; Martin-Fernandez M; de Coo I; Dudink J; de Vries FA; Bertoli Avella A; Prinz M; Crow YJ; Verheijen FW; Pellegrini S; Bogunovic D; Mancini GM
    J Exp Med; 2016 Jun; 213(7):1163-74. PubMed ID: 27325888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
    Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
    Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.